Brepocitinib Improves Mild to Moderate AD in Phase 2b Trial ...Middle East

In addition to AD, brepocitinib, a topical TYK2/JAK1 inhibitor, is being developed as a treatment for dermatomyositis, SLE, hidradenitis suppurativa, and non-infectious uveitis. MDedge News

Read More Details
Finally We wish PressBee provided you with enough information of ( Brepocitinib Improves Mild to Moderate AD in Phase 2b Trial )

Also on site :

• Numbrix 9 - June 18
• BACK
• A look at six bills in Albany awaiting Gov. Hochul’s signature